Form 4: Medpace CEO Sells Shares via Pre-Arranged Trading Plan

Medpace Holdings CEO August J. Troendle sold 28,688 shares of common stock for approximately $17 million through a pre-arranged trading plan.

Summary

• August J. Troendle, CEO, Director, and 10% Owner of Medpace Holdings, Inc. (MEDP), reported sales of common stock.
• On November 20, 2025, 6,830 shares were sold at a weighted average price of $598.49 per share.
• On November 21, 2025, an additional 21,858 shares were sold at a weighted average price of $592.18 per share.
• The total number of shares sold across both transactions is 28,688.
• The transactions were executed pursuant to a limit order placed by the Reporting Person during an open window period, indicating a Rule 10b5-1(c) trading plan.
• Following these transactions, Mr. Troendle directly beneficially owns 833,627 shares of common stock.
• He also indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he is the sole manager and controlling unit holder.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the disclosure that it was conducted under a Rule 10b5-1 plan mitigates concerns about opportunistic selling or lack of confidence, indicating a pre-scheduled personal financial management decision.

Positives

• The sales were conducted under a Rule 10b5-1(c) trading plan, indicating a pre-scheduled transaction rather than an opportunistic sale based on new, non-public information. This suggests a structured approach to personal financial management and adherence to compliance.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the direct ownership stake of a key executive, which some investors might interpret as a slight decrease in alignment of interests, though this is mitigated by the pre-planned nature.

Risks

• While the sale was pre-planned, a significant reduction in direct insider ownership could, in some contexts, be perceived as a potential signal of reduced confidence, although the Rule 10b5-1 plan mitigates this interpretation.

Future Outlook

NA

Management Comments

• "The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period."
• "The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ('MPI') and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."

Industry Context

This Form 4 filing is specific to an insider transaction and does not provide information related to broader industry trends or competitive landscape.

Corporate Governance

Related Party Transactions

• August J. Troendle indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he is the sole manager and controlling unit holder. He disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may observe a reduction in direct insider ownership, though the 10b5-1 plan context generally lessens negative interpretations regarding management's confidence in the company.

Key Dates

Recommendation

The filing details a pre-arranged insider sale by the CEO under a Rule 10b5-1 plan. Such planned sales are typically for personal financial management (e.g., diversification, liquidity) and do not inherently signal a change in the company's fundamental outlook or the insider's confidence. Therefore, this specific transaction alone does not warrant a change from a 'hold' position, as it's a routine, pre-scheduled event rather than an opportunistic sale.

Keywords

Medpace, MEDP, August J. Troendle, insider sale, Form 4, CEO, director, 10% owner, Rule 10b5-1, stock transaction, beneficial ownership